US 11,773,162 B2
Anti-Siglec-7 antibodies for the treatment of cancer
Christopher Bebbington, San Carlos, CA (US); Wouter Korver, San Carlos, CA (US); Nenad Tomasevic, San Carlos, CA (US); Suzy El Bader, San Carlos, CA (US); and Kenneth Luehrsen, San Carlos, CA (US)
Assigned to Allakos, Inc., San Carlos, CA (US)
Appl. No. 16/323,442
Filed by Allakos, Inc., San Carlos, CA (US)
PCT Filed Aug. 4, 2017, PCT No. PCT/US2017/045641
§ 371(c)(1), (2) Date Feb. 5, 2019,
PCT Pub. No. WO2018/027203, PCT Pub. Date Feb. 8, 2018.
Claims priority of provisional application 62/371,680, filed on Aug. 5, 2016.
Prior Publication US 2019/0194323 A1, Jun. 27, 2019
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
OG exemplary drawing
 
1. An anti-Siglec-7 antibody that binds to Siglec-7 and comprises:
(a) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDY (SEQ ID NO:81), an an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(b) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDY (SEQ ID NO:81), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(c) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDV (SEQ ID NO:91), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(d) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDV (SEQ ID NO:91), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLED (SEQ ID NO:103), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(e) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(f) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLED (SEQ ID NO:103), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(g) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(h) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:9 2), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLED (SEQ ID NO:103), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(i) an HCDR1 sequence GYDFSNY (SEQ ID NO:89), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(j) an HCDR1 sequence GYDFSNY (SEQ ID NO:89), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDI (SEQ ID NO:92), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95);
(k) an HCDR1 sequence GYDFSNY (SEQ ID NO:89), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDY(SEQ ID NO:81), an LCDR1 sequence RASQNIHNYLA (SEQ ID NO:100), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95); or
(l) an HCDR1 sequence GYDFSNF (SEQ ID NO:79), an HCDR2 sequence YPGDGE (SEQ ID NO:80), an HCDR3 sequence DDYLRAMDV (SEQ ID NO:91), an LCDR1 sequence RASGNIHNYLA (SEQ ID NO:93), an LCDR2 sequence SAKRLES (SEQ ID NO:94), and an LCDR3 sequence QHFWSSPYT (SEQ ID NO:95).